Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 6, 2018
Previous Article Next Article

Thalidomide-type teratogenicity: structure–activity relationships for congeners

Author affiliations

Abstract

Unravelling the molecular basis of thalidomide embryotoxicity, which is remarkably species–specific, is challenging in view of its low toxicity in the mature animal. Employing data derived solely from proven sensitive primate species or susceptible strains of rabbit, the structure–activity relationship of over 50 compounds which are, arguably, congeners of thalidomide has been reviewed. The molecular requirement for ‘thalidomide-type’ teratogenicity was highly structure dependent. Both the phthalimide and glutarimide groups were essential for embryopathic activity, although minor substitutions in either or both rings could be tolerated without a loss of toxicity. An α-linkage between the two cyclic structures was essential; a β-link resulted in a complete loss of embryopathic activity. Crucially, this α-configuration provided a centre of asymmetry enabling the existence of stereoisomers. The thalidomide molecule is not a static entity and under physiological conditions it undergoes a number of intra- and inter-molecular reactions. Besides irreversible hydrolysis, its keto–enol tautomerism, base-assisted proton transfer and glutarimide ring rotation lead to rapid interconversion of the thalidomide enantiomers. These enantiomers form equilibria between themselves and also between both homochiral and heterochiral dimers. It is proposed that the more energetically favourable and stable heterochiral dimer of thalidomide is an active agent that possesses the structural features of the paired nucleotides of the double-stranded DNA. Its capacity to enter into hydrogen bonding interactions affects DNA expression in a chaotic manner without causing permanent mutations. This disruption may well be concentrated at nucleotide sites known to be involved in specific promoter regions of the genome.

Graphical abstract: Thalidomide-type teratogenicity: structure–activity relationships for congeners

Back to tab navigation

Article information


Submitted
16 Jul 2018
Accepted
18 Sep 2018
First published
26 Sep 2018

Toxicol. Res., 2018,7, 1036-1047
Article type
Review Article

Search articles by author

Spotlight

Advertisements